search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
UNIVERSAL CONDENSATE PUMPS SAT NEWS


are not yet deployed everywhere. For temperature ranges below -70°C, if they exist, the solutions remain even more confidential. Regulations, standards and labels have been developed over the last 70 years at regional, national or global level to guarantee the quality of this cold chain. Since its creation in 1908, the IIR has been actively involved in this, and has been a partner of the United Nations since 1970 for the implementation of the agreement on the transport of perishable foodstuffs, known as the ATP agreement, but also of the World Health Organisation (WHO), which is deploying its quality and safety programme (PQS) for the vaccine cold chain. The IIR has also supported the International Healthcare ColDays of the French Association of Refrigeration (AFF) since 2008 and has co-published the best practice guide on the cold chain for health products.


What prospects for the temperature- controlled logistics of the Covid-19 vaccine? While the cold chain for health products - and more particularly vaccines - can efficiently deliver vaccines at +2°C/+8°C almost anywhere in the world, this is not necessarily the case for large-scale vaccination campaigns with products to be stored below -20°C, and even less so at -80°C. The challenge is unprecedented, but the battle is not lost.


For below -20°C products, existing and widely used solutions for frozen products can quickly be duplicated in the vaccine cold chain. They are well known, controlled, available and, in some cases, already certified. For below -80°C products, the situation is more complex, but not hopeless. Although there is currently no significant storage and transport capacity for thermosensitive products below -80°C, technical solutions do exist. As regards storage, the air-source open-cycle refrigeration machines used for refrigeration in tuna warehouses at -60°C, for example, can also be used at -80°C.


They can also be used for cold distribution chambers. For transport, nitrogen cryogenic transport units used at -20°C can also be used at -80°C with reinforced insulation boxes. If we are talking about temperatures close to -80°C, as is often the case with health products, then dry ice plays an important role in transport, especially in insulated packaging and containers both for air transport and for land transport in combination with refrigerated trucks. There are already cabinets for storage at -80°C, especially in hospitals and laboratories. Finally, the readjustment of the temperature of these products prior to injection should not be neglected: it is not innocuous to go from -80°C to +20°C. And launching a massive vaccination campaign with products below -80°C requires determining these means, deploying them on a large scale and training the users of this equipment. Conclusions


The temperature-controlled logistics of the global massive vaccination against Covid-19 is a real challenge, as much for its unprecedented importance as for its technical specificity, as announced by several laboratories. Whether at temperatures below -20°C or -80°C, for all or part of the chain, new means will have to be put in place with costs significantly higher than typically implemented for vaccine logistics. This is a matter for experts and specialists. The most precise information, particularly concerning temperature requirements, must be made available as soon as possible. The IIR and its hundreds of experts around the world are at the forefront of these issues and will provide their scientific and technical expertise on the cold chain for health products to the public and private players involved in these operations: governments, health agencies, hospitals, pharmaceutical laboratories and, more broadly, health and logistics professionals. All these experts are already at work to provide concrete answers and face the challenge of the global massive Covid-19 vaccination.


GOBI II / COMBI THE M LT FEATURE POWERHOUSEATURE P ULTI- NEWS COMBI


GOBI II


   


Unsurpassed functionality in the condensate pumps from REFCO. Everything you want to 


Refco


6,000 up to 120,000 Btu/H (1.75 kW t o 35 kW)


Universal application 6,000 up to 120,000 Btu/H


Diagnostic LED


Ensures cor ect initial installation and assists in diagnost ics


Ensures correct initial diagnostics


ionality in the condensat . Everything you want t 


Powerful operation Up to 42 liter per hour 3 meter suction 20 meter lif t


  to AC unit capacit y


Quiet mode - 20dbA     


ode - 20dbA 


  Warranty period starts with pump installation


 arranty period starts allation


Digital sensor Unique digital wat


Unique digital water level sensor


www.condensate-pumps.com www.acr-news.com


REFCO Manufacturing Ltd. Industriestrasse 11


REFCO M 6285 Hitzkirch - Switzerland


Industriestrasse 11 6285 Hitzkirch - Swit


info@refco.ch .ch


+41 41 919 72 82 info@r efco


December 2020 15


www .refco.ch


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44